Agilent Enters into a Collaboration Agreement with Incyte to Advance the Development of Companion Diagnostics
Shots:
- Agilent signed a collaboration agreement with Incyte to leverage Agilent’s expertise in the development of companion diagnostics (CDx) for the development and commercialization of hematology and oncology portfolio
- The collaboration integrates both companies to collaborate on CDx development programs. Through the agreement, Agilent expects to expand its companion diagnostic portfolio with novel biomarkers
- Moreover, the collaboration gives Incyte the leverage to use Agilent’s expertise in IVD assay development, global regulatory approvals & commercialization to support clinical trials, potential registration & commercialization of CDx in the US & EU
Ref: Agilent | Image: Incyte
Related News:- Incyte Presents Positive 52-Week P-IIb Trial Results of Povorcitinib (INCB54707) for Extensive Nonsegmental Vitiligo at EADV 2023
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
